RVL Pharmaceuticals plc Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from 2017 to 2022
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
RVL Pharmaceuticals plc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2017 to 2022.
- RVL Pharmaceuticals plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2023 was -$23.9M, a 97.3% decline year-over-year.
- RVL Pharmaceuticals plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending June 30, 2023 was -$68.3M, a 25.8% decline year-over-year.
- RVL Pharmaceuticals plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$53.4M, a 12.5% increase from 2021.
- RVL Pharmaceuticals plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$61M, a 23.4% increase from 2020.
- RVL Pharmaceuticals plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2020 was -$79.6M, a 70.7% increase from 2019.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)